ALung is now proud to be part of LivaNova.

HEMOLUNG Registry Program

ALung developed the HEMOLUNG Registry Program as part of our commitment to improving the treatment and outcomes of acute respiratory failure patients. The HEMOLUNG Registry Program collects de-identified, real-world patient and Hemolung therapy data to formulate and sustain sound safety, scientific and quality evidence.  

Participation in the HEMOLUNG Registry Program is designed to be a simple process. Contributors are asked to record patient and therapy related information on the HEMOLUNG Registry Form and return the form to ALung via email. 

Contributors may also request data from the Hemolung Registry to support research questions. Data requests are considered on a case-by-case basis by ALung’s Clinical Science team and Clinical Advisory Board. 

HEMOLUNG Registry ProgramResources 

HEMOLUNG Registry Form Fillable PDF (for best compatibility use desktop Adobe) 
HEMOLUNG Daily Monitoring Record Sheet (additional pages) 
HEMOLUNG Daily Blood Gas Sheet (additional pages) 


HEMOLUNG Difference
HEMOLUNG Publications

Indication for Use: The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.